Nelson Advisors Big Questions in HealthTech Series: Is Venture Capital right for MedTech? Should more European MedTech be funded by debt, royalties or strategics from day one?
- Nelson Advisors
- 2 hours ago
- 16 min read
Re-Evaluating the Capital Stack in European MedTech: Structural Mismatch, Day-One Realities and the Alternative Finance Paradigm
The financing of European medical technology is undergoing a structural transition that challenges the viability of its historical funding mechanisms. For decades, early-stage medtech innovation relied on the traditional venture capital model, which was originally pioneered to support the rapid scaling, high gross margins, and predictable, capital-efficient exit pathways of the software industry.
However, the combination of physical hardware development timelines, complex and localised national reimbursement frameworks, and the operational demands of the EU Medical Device Regulation (MDR) has exposed a fundamental mismatch between the investment horizon of venture capital and the development cycles of modern medical technologies.
This mismatch is reflected in a severe contraction in growth-stage venture capital. While early-stage seed and Series A valuations have shown nominal resilience, the volume of capital available for subsequent rounds has collapsed. Total investment in growth-stage healthcare in late 2024 was 84% lower than its peak in late 2021, creating a severe supply-demand bottleneck as a surplus of Series A companies compete for a dwindling pool of follow-on growth capital. This venture funding gap is compounded by a dramatic decline in fundraising. Early-stage life sciences venture fundraising plummeted by over 80% from 2021 to 2022, and despite a partial rebound, it remains 46% below 2021 levels, meaning that the "dry powder" accumulated during the pandemic boom has been largely exhausted. At the same time, regulatory changes under the Capital Requirements Regulation (CRR) and Capital Requirements Directive (CRD) have raised the cost of bank investments in private equity and venture capital funds, further restricting the flow of institutional capital into high-risk asset classes.
Consequently, the European medtech ecosystem has entered an era of "industrial maturity". This phase is characterised by a departure from the "growth at all costs" paradigm that defined the zero-interest-rate policy (ZIRP) era. Valuation metrics have shifted from speculative user-acquisition numbers to strict fundamentals, clinical validation, unit economics, and risk-mitigated regulatory positioning. To maintain global competitiveness, European medtech must evaluate alternative capital formation strategies.
The Regulatory and Commercial Double Squeeze: MDR and European Fragmentation
European medtech companies operate under a "double squeeze" characterised by structurally high cash requirements and incompressible development timelines. This operational challenge has been heavily exacerbated by the implementation of the EU Medical Device Regulation (MDR 2017/745) and the In Vitro Diagnostic Regulation (IVDR 2017/746). These legislative frameworks have fundamentally altered the economics of product development by creating a capital-intensive barrier to entry.
The operational burden of obtaining and maintaining a CE mark under the current regulatory framework is substantial. MedTech Europe survey data indicates that the average time required for a medical device manufacturer to complete a Quality Management System (QMS) assessment is 19.5 months, while the Technical Documentation Assessment (TDA) averages 21.8 months. For in vitro diagnostic (IVD) manufacturers, both QMS and TDA certifications require an average of 18 months. Over half of this timeline is spent in administrative "pre-review" and "certificate issuance" phases rather than active scientific or technical review.
Furthermore, financial compliance costs have escalated. For a single device, average Notified Body fees for initial MDR QMS and TDA certifications reach €136,981 and €176,202 respectively, while IVDR certifications demand €108,307 and €64,184. Crucially, 90% of a manufacturer's total compliance cost is driven by the internal personnel required to compile, manage, and maintain the necessary technical documentation.
These escalating costs and prolonged timelines have had a chilling effect on innovation. Manufacturers are increasingly reluctant to modify existing CE-marked devices, raising concerns about the long-term availability of cutting-edge clinical tools in Europe. This regulatory burden is particularly threatening to special patient populations, creating an acute crisis in "orphan devices". An estimated 26.6% of IVD manufacturers plan to transition less than 5% of their orphan device portfolios to the IVDR, and 29% of medical device manufacturers do not plan to transfer any of their current orphan devices to the MDR.
This regulatory gridlock is worsened by an acute shortage of specialised human capital: 91% of SME medical device manufacturers and 86% of large corporations report extreme difficulty securing qualified regulatory affairs employees. This operational strain is further compounded by the introduction of the EU AI Act, which enforces strict compliance standards for high-risk artificial intelligence systems beginning in March 2026. This regulation creates a binary filter for healthtech investment: medical AI tools using "Black Box" models are rendered un-investable in European clinical settings, forcing venture funds to redirect capital exclusively toward explainable "Glass Box" architectures built with "privacy-by-design" principles.
Once regulatory clearance is obtained, European commercialisation remains highly fragmented. Unlike the single-payer Medicare model or unified private insurer codes in the United States, Europe is a patchwork of regional and national healthcare systems, each maintaining distinct budgeting, procurement, and reimbursement frameworks.
Only a limited number of European countries operate unified innovative payment schemes (IPS) covering digital health or medical devices. Navigating these disparate frameworks requires localised clinical evidence, pricing negotiations, and stakeholder engagement, adding years of post-clearance timeline before achieving meaningful commercial scale.
Regulatory and Economic Metric | European Union (MDR / IVDR) | United States (FDA 510(k)) |
Average QMS Assessment Timeline | 18.0 to 19.5 months | Minimal pre-market QMS review for standard 510(k) |
Average Technical Review Timeline | 18.0 to 21.8 months | 3.9 months standard (10 months average filing-to-clearance) |
Typical Initial Regulatory Fees | €136,981 (QMS) + €176,202 (TDA) | $5,440 (Small Business) / $21,760 (Standard 510(k)) |
Premarket Evidence Standard | Mandatory clinical evaluation for all risk classes | Substantial equivalence to predicate device |
Regulatory Predictability Rating | 22% of manufacturers rate as highly predictable | 62% of manufacturers rate as highly predictable |
Primary Systemic Value Driver | Cost-minimization and administrative budget relief | Top-line revenue generation and procedure enablement |
To mitigate these regulatory and commercial bottlenecks, the European Union has launched targeted interventions. On April 28th, 2026, the European Commission, the Medical Device Coordination Group (MDCG), and the European Medicines Agency (EMA) initiated a "breakthrough pilot" designed to establish an accelerated pathway for highly innovative medical devices and in vitro diagnostics addressing unmet needs in serious or life-threatening conditions.
This pilot program, which begins with cardiovascular technologies, aims to improve pre-market coordination between regulators, expert panels, and Notified Bodies to replicate the success of the U.S. FDA’s Breakthrough Devices Program. Under the FDA program, designated devices achieve significantly accelerated approvals, with mean decision times of 152 days for the 510(k) pathway and 262 days for the De Novo pathway. However, historical FDA data reveals that only 12.3% of the 1,041 designated breakthrough devices eventually secure marketing authorisation, demonstrating that accelerated regulatory pathways do not eliminate the underlying developmental and commercial execution risks.
Furthermore, the EU is implementing the Health Technology Assessment Regulation (HTAR) to harmonise joint clinical assessments across the Union beginning in 2026, and is proposing a comprehensive "Biotech Act" to modernise permitting, reduce clinical trial approval timelines from 106 to 75 days and establish a Health Biotechnology Investment Pilot with the European Investment Bank (EIB) to mobilise private risk capital.
The Strategic Pivot: Implementing a US First Strategy
The friction of the EU MDR framework has triggered a significant shift in market entry strategies. Historically, medtech companies launched new products in Europe first, utilizing the CE mark as a faster, more predictable path to clinical validation before attempting the FDA pathway. Today, the reverse is true.
European medical device startups are increasingly executing "US-first" commercialisation roadmaps, relegating their domestic European market to a secondary phase. Since the implementation of MDR, the preference for the EU as a first-launch destination has dropped by 33% for large medical device manufacturers and 19% for SMEs.
This strategic pivot is driven by the structural predictability of the FDA's regulatory framework. The FDA provides established pathways, such as the 510(k) Premarket Notification, the De Novo pathway for novel moderate-risk devices, and the Premarket Approval (PMA) process for high-risk technologies.
Through formal pre-submission (Q-sub) meetings, developers can engage in early, iterative dialogue with FDA review teams to align on clinical trial designs, endpoints, and human factors testing before submitting formal applications. This structure reduces regulatory risk, a stark contrast to Europe where Notified Bodies are legally restricted from providing pre-application consulting or clinical strategy feedback.
Beyond regulatory predictability, the economic architecture of the United States healthcare market offers superior scaling dynamics. The European purchasing environment is largely driven by public healthcare systems focused on cost-minimisation, administrative procurement, and long, bureaucratic hospital purchasing cycles.
In contrast, the U.S. system operates on a revenue-generation model. Private health systems, ambulatory surgery centres, and hospital networks prioritise clinical innovations that increase operational throughput, enable high-margin procedures, or attract premium clinical talent.
The presence of a single, highly integrated commercial market with clear, nationally recognized reimbursement codes (such as CPT and ICD-10 codes) allows medtech startups to establish immediate commercial traction. This early revenue generation is critical; it provides the cash flow and operational proof points required to attract late-stage strategic acquirers or secure non-dilutive credit facilities, ultimately bypassing the need for highly dilutive growth-stage European venture rounds.
The Day One Funding Paradox: Why Debt and Royalties Fail at Inception
The severe contraction in early-stage venture capital has led some market participants to propose that European medtech should be funded from "day one" by alternative financial instruments, specifically debt and royalty-based structures. However, this proposal overlooks the underwriting criteria and structural mechanics of these financial instruments. Debt and royalties are fundamentally unsuited for funding seed-stage, pre-revenue medical technology companies.
Venture debt is not an independent source of capital; it is a leverage multiplier designed to complement recent equity raises. Underwriters do not evaluate a pre-revenue startup’s cash flow or physical assets. Instead, they underwrite venture debt based on the company's ability to raise subsequent rounds of equity capital from institutional venture sponsors.
A typical venture debt facility is structured to represent 25% to 35% of a freshly closed Series A or Series B equity round, providing a non-dilutive cushion to extend the cash runway between major financing events. Without a professional institutional sponsor anchoring the cap table, venture debt providers cannot price the risk or execute the transaction.
Furthermore, servicing venture debt requires cash outflows in the form of interest payments and amortization schedules, which increases immediate cash burn for a pre-commercial startup. Private credit providers are engaging earlier than in previous cycles, but their underwriting remains strictly targeted at companies that already demonstrate clear revenue visibility, strong unit economics, or a highly credible path to near-term scale.
Similarly, royalty interest financing and revenue-based financing (RBF) cannot function at inception. These models are built on the monetization of existing, predictable cash flows. In a traditional royalty transaction, an investor purchases a portion of an existing royalty stream generated under an active licensing agreement with a larger strategic partner. In a synthetic royalty transaction, an organisation creates a new royalty stream based on the future net sales of its own proprietary product.
While synthetic royalties have expanded to development-stage assets, royalty investors are historically unwilling to fund pre-commercial projects that have not completed pivotal clinical trials and established a clear path to regulatory approval. Pre-commercial assets face profound regulatory, manufacturing, and commercial launch risks that cannot be underwritten by yield-focused royalty funds.
Furthermore, recent legal precedents in the United States, such as the Sanofi-Aventis U.S. LLC v. Mallinckrodt plcbankruptcy proceedings, have established that unsecured royalty streams can be restructured or discharged in insolvency. Consequently, modern synthetic royalty transactions require comprehensive, senior secured pledges over intellectual property and other product assets. For a day-one startup, which possesses unproven intellectual property and zero commercial traction, the collateral base is insufficient to support a structured royalty monetisation.
Constructing the Modern MedTech Capital Stack: From Day One to Commercial Scale
Because debt and royalties are structurally unavailable at inception, European medtech startups must construct a multi-layered capital stack that sequences different funding sources as the technology climbs the Technology Readiness Level (TRL) and regulatory ladder.
At the earliest stages of ideation, target validation, and prototype design, the capital stack should be anchored by non-dilutive public grants and tax credits. This public-private intervention allows university technology transfer offices and academic spin-outs to mature promising innovations before formal company creation.
Targeted Translational Grants: Programs like the Medical Research Council-backed Target Validation Scheme (TAS) in the UK provide non-dilutive grants of up to £80,000 to validate biological targets and generate early IP, enabling tech transfer offices to attract institutional capital.
Structured European Programs: On a pan-European level, the Horizon Europe framework and the EIC Pathfinder and Transition programs provide non-dilutive grants of up to €4 million to nurture radical concepts at TRL 1-4.
R&D Tax Incentives: Startups can leverage R&D tax credit schemes to fund early development. For example, the Australian R&D Tax Incentive provides direct cash rebates for clinical and preclinical expenditures, allowing early-stage companies to progress with minimal equity dilution.
Phase II: Early Strategic Alliances and Family Office Syndication (TRL 5-8)
As the medical device enters clinical evaluation and regulatory submission preparation, the capital requirements escalate, and the risk profile shifts. At this stage, matching with patient capital and strategic industry networks is critical.
Family Offices as "Patient Capital": Traditional venture funds are constrained by a 7-to-10-year fund cycle and focus on IRR, which can pressure companies to seek premature exits. In contrast, family offices deploy their own wealth, allowing them to operate on evergreen timelines and focus on long-term Multiple on Invested Capital (MOIC). They provide the long-term support required to survive multi-year clinical trials and Notified Body backlogs. Furthermore, family offices are increasingly forming syndicates to pool resources and share operational diligence. A notable example is the €95 million Series B round for Diagnostics France, which was anchored by the public BPI France alongside the Bettencourt family office (Téthys Invest) and the Mulliez family office.
Strategic Corporate Partnerships and CVCs: Engaging with Corporate Venture Capital (CVC) arms (such as J&J Development Corporation, Medtronic Ventures, or Abbott Ventures) from day one offers significant advantages. CVCs provide more than capital; they offer clinical trial design support, regulatory expertise, and manufacturing infrastructure. Unlike traditional financial VCs, strategics are often motivated by long-term pipeline integration rather than quick exits, making them more likely to stick with a company through regulatory delays. For example, BMS and Novo Nordisk actively use early-stage licensing, co-development and equity tools to secure proprietary options on promising clinical platforms.
Phase III: Venture Debt, Private Credit, and Synthetic Royalties (TRL 9+)
Upon securing regulatory clearance (FDA approval or MDR CE mark) and entering the commercialisation phase, the company can finally unlock structured credit and royalty instruments to fund commercial scaling, launch logistics, and inventory expansion.
Commercial Venture Debt and Private Credit: Once early revenue visibility is achieved, specialized lenders can provide structured credit lines. At this stage, scale-ups can access larger public facilities. The European Investment Bank (EIB) provides structured venture debt facilities ranging from €10 Million to €50 Million for SMEs and mid-caps developing highly innovative technologies within the EU.
Synthetic Capped Royalties: Commercial-stage companies can monetize their product’s future cash flows by establishing a synthetic royalty. Under a capped structure, an investor provides upfront growth capital in exchange for a percentage of net sales (typically 6% to 8%), with the contract terminating once a pre-determined return multiple (e.g., 2.25x) is achieved. This non-dilutive structure is highly flexible, aligning debt service directly with fluctuating quarterly sales without imposing restrictive financial covenants.
Market Bottlenecks and Policy Barriers in the European Capital Landscape
While alternative financial instruments offer a theoretical roadmap to scale, the European medtech ecosystem remains constrained by severe structural and policy barriers. Compared to the United States, Europe lacks the financial market breadth and depth required to support deep-tech and life sciences enterprises through their entire growth cycle.
A primary systemic hurdle is the lack of institutional capital participation, particularly from pension funds. Regulatory frameworks in Europe, such as those under the Solvency II and capital requirements regimes, historically discourage pension funds and insurance companies from investing in unlisted, long-term, and high-risk assets. Unlocking even a modest additional share of pension fund assets through targeted reforms could expand the capital available for early-stage life sciences innovation.
Additionally, tax-incentivised investment schemes maintain structural limitations. In the United Kingdom, the Enterprise Investment Scheme (EIS) and Venture Capital Trusts (VCTs) are essential for mobilizing private retail capital into early-stage knowledge-intensive companies (KICs). However, these schemes enforce strict age and size limits:
Age Limits: Companies are restricted from accessing EIS/VCT capital if they are past a 7-to-10-year age limit from their first commercial sale. For medtech hardware startups navigating protracted clinical trials and regulatory delays, this timeline is disproportionately restrictive, locking them out of vital scaling capital.
Asset and Employee Caps on Options: The Enterprise Management Incentive (EMI) scheme allows SMEs to compete with large corporations for elite technical and regulatory talent by granting tax-favored stock options. However, the gross assets cap of £30 Million and the 250 employee limit have remained unchanged since the early 2000s, preventing high-growth medtech scale-ups from utilising this recruitment tool.
Structural Exit Dynamics, The Series B Gap and The Platform Playbook
The public and private equity markets in Europe are navigating a period of profound structural realignment. The historical "escalator" model of venture capital, where a Series A round leads predictably to a Series B growth round, Series C scaling and a public IPO, has broken down for the vast majority of medtech market participants. In its place, several distinct exit and consolidation trends have emerged.
The Exit Backlog Paradox and the Frozen IPO Window
A stark "exit backlog paradox" characterises the late-stage ecosystem. Dozens of late-stage healthcare platforms raised billions of dollars in venture funding at peak historical valuations during the 2020–2021 bubble. Having grown to immense operational scale, these platforms have outgrown the acquisition capacity of standard corporate buyers. Consequently, they must access public equity markets to achieve liquidity.
However, the public IPO window in Europe remains highly selective. In the first half of 2026, while broader healthcare sectors successfully accessed public capital, such as biotechnology companies raising over $1 Billion and emergency transport provider GMR Solutions pricing a $479 Million listing, not a single core digital health or medtech platform completed an IPO.
This freeze sharply contrasts with a brief opening in mid-2025, which saw listings by Hinge Health ($437 Million raised at a $2.6 Billion valuation), Omada Health ($150 Million raised), and medical supply giant Medline ($6.26 Billion listing). The closed public window has forced late-stage crossover investors (such as Fidelity and Wellington) to shift to capital-preservation strategies, funding selective bridge rounds to sustain balance sheets until a viable public window opens.
Venture-to-Venture (V2V) Consolidation
As a direct consequence of the Series B funding gap and frozen public markets, early-stage startups are increasingly forced to seek liquidity events significantly earlier in their lifecycle, a phenomenon termed the "Series A Off-Ramp". Rather than attempting to scale independently across fragmented borders, startups are pursuing venture-to-venture (V2V) consolidation, which accounted for approximately 75% of recorded healthtech acquisitions in the first half of 2025.
In these transactions, late-stage, well-capitalised "Scale-Ups" utilise their stock and balance sheets to acquire early-stage, highly specialised startups. This integration is driven by several strategic needs:
Regulatory Speed: Acquiring a local competitor with pre-existing regional regulatory listings (such as a DiGA listing in Germany or HAS approval in France) provides an immediate cross-border foothold, bypassing years of local bureaucratic delay.
Clinical and AI Tuck-Ins: Platforms are acquiring specialised clinical AI models to build comprehensive, multi-product enterprise platforms capable of delivering quantifiable operational returns to health systems.
Programmatic V2V acquisition strategies illustrate this trend:
The Huma Ecosystem: Supported by an $80 Million Series D round, Huma has executed a programmatic platform consolidation strategy. It acquired iPLATO to secure patient engagement tools and primary care contracts; Alcedis to establish a data-driven clinical trials division; and eConsult, a primary and urgent care digital triage platform serving over 1,800 GP practices. By integrating these point solutions, Huma constructed an end-to-end platform embedded directly into the NHS App.
Mental Health Consolidation: Stockholm-based digital therapy provider Mindler acquired the UK telecare business of ieso Digital Health for an estimated £20 Million to combine its video-based platform with ieso’s typed CBT interface and clinical AI tools. Mindler also acquired Finnish outcome-analytics startup Medified to embed tracking software into its therapeutic platform.
Private Equity (PE) "Buy-and-Build" and Multiple Arbitrage
Simultaneously, private equity sponsors are moving downstream into the middle and lower-middle markets to capitalise on depressed valuations. Utilising programmatic "buy-and-build" playbooks, PE firms are acquiring fragmented clinical practices and medical device suppliers at low multiples (typically 6x to 8x EBITDA) and integrating them into pan-European platforms.
Once integrated, these consolidated platforms command premium exit multiples (typically 12x to 15x EBITDA) from sovereign wealth funds or larger financial institutions, driving significant non-dilutive value creation through multiple arbitrage. Geographically, this PE descent is highly active in Southern and Eastern Europe (such as Spain, Italy, and Poland), where the market remains fragmented relative to Northern Europe.
Valuation Multiples and Transaction Benchmarks
The current healthcare M&A market is entering a period of measured valuation recalibration. Across all sectors, the global median EV/EBITDA multiple for M&A transactions has recovered to 12.7x, down from 14.9x in 2024, reflecting sustained buyer scrutiny and heightened discipline.
The median TEV/Revenue figure has compressed to 3.04x, the lowest level in four years, signalling that revenue quality and reimbursement stability are being priced with high precision.
Sub sector Category | Typical EV / EBITDA Multiple | Typical EV / Revenue Multiple | Primary Growth and Valuation Catalyst |
Surgical Robotics | 15x to 25x+ | 8.0x to 20.0x | High growth expectations; razor-and-blade platform model; proprietary consumables. |
Cardiovascular Devices | 12x to 18x | 4.0x to 7.0x | Strong public/private reimbursement; high procedure volume growth; strategic M&A competition. |
AI/ML-Enabled Diagnostics | 14x to 20x | 6.0x to 10.0x | High gross margins; explainable clinical datasets; deep workflow integration. |
Orthopedics | 10x to 14x | 3.0x to 5.0x | Procedure volume recovery; shift of clinical procedures to ambulatory surgery centers. |
General Medical Devices | 8x to 12x | 3.0x to 5.0x | Strength of underlying patent portfolio; regulatory clearance positioning (MDR-ready). |
Contract Manufacturing (CDMO) | 8x to 12x | 2.0x to 4.0x | Long-term revenue visibility; level of customer concentration risk. |
The valuation spectrum is highly bifurcated between large-cap diversified conglomerates and high-growth pure-plays. A large-cap diversified device company (such as Medtronic or Becton Dickinson) trades within a predictable range of 13x to 18x forward EBITDA, whereas a high-growth pure-play in a highly competitive category (such as structural heart or robotic surgery) consistently commands premium multiples of 18x to 30x EBITDA.
Furthermore, applying software’s "Rule of 40", where a company’s organic revenue growth rate plus its EBITDA margin should exceed 40%, has become a standard metric in medtech valuation. Companies that exceed the Rule of 40 consistently trade at premium multiples, while those below it are heavily discounted.
These valuation dynamics are illustrated by recent transaction benchmarks:
Johnson & Johnson / Shockwave Medical (2024): Acquired for approximately $13.1 Billion, representing an implied multiple of ~18x EV/Revenue and ~54x EV/EBITDA, driven by Shockwave’s high-growth intravascular lithotripsy (IVL) technology platform.
Stryker / Wright Medical (2020): Acquired for ~5-6x EV/Revenue and ~35x EV/EBITDA, reflecting Wright’s established extremities and biologics portfolio.
Boston Scientific / BTG (2019): Acquired for ~7x EV/Revenue and ~25x EV/EBITDA to serve as a high-margin interventional medicine platform.
Conclusion
Venture capital is a mismatched financial instrument when applied as a single source of capital across the entire medtech development lifecycle. The structural friction of the EU MDR, combined with localised reimbursement fragmentation and incompressible clinical timelines, has broken the traditional venture capital "escalator" in Europe.
However, the proposal to fund medtech from "day one" utilising debt or royalties is a structural impossibility due to the underwriting standards of these credit and yield-based instruments.
The solution for European medtech is the construction of a diversified capital stack. Founders must sequence public non-dilutive grants and tax incentives to fund early-stage R&D; transition to patient, evergreen family offices and strategic corporate venture capital to navigate clinical validation and regulatory review; and unlock venture debt, private credit and synthetic capped royalties only after securing regulatory clearance and establishing commercial revenue visibility.
By re-engineering the capital stack to match capital structures with underlying asset risk, European medtech can bypass the growth equity bottleneck, preserve founder equity, and bring clinical innovations to patients globally.
Nelson Advisors > European MedTech and HealthTech Investment Banking
Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk
Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital
Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb
Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk
#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech
Nelson Advisors LLP
Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT
Meet Nelson Advisors @ 2026 Events
Digital Health Rewired > March 2026 > Birmingham, UK
NHS ConfedExpo > June 2026 > Manchester, UK
HLTH Europe > June 2026, Amsterdam, Netherlands
HIMSS AI in Healthcare > July 2026, New York, USA
Bits & Pretzels > September 2026, Munich, Germany
World Health Summit 2026 > October 2026, Berlin, Germany
HealthInvestor Healthcare Summit > October 2026, London, UK
HLTH USA 2026 > October 2026, USA
Barclays Health Elevate > October 2026, London, UK
Web Summit 2026 > November 2026, Lisbon, Portugal
MEDICA 2026 > November 2026, Düsseldorf, Germany
Venture Capital World Summit > December 2026 Toronto, Canada
Comments